Abstract: The present disclosure provides a dental bleaching guide plate, including a first plate and a second plate, wherein the first plate and the second plate are abutted to form an enclosed deep groove structure, the first plate is provided with a guide hole, a spacing between two opposite side surfaces of the first plate and the second plate is greater than an outer diameter of a neck of a tooth, and there is a gap between the side surfaces of the first plate and the second plate and side surfaces of the tooth. The guide plate can be sleeved onto an exterior of a tooth to inhibit a bleaching agent from coming into contact with other teeth. In addition, a range and an amount of applying a bleaching agent can be accurately controlled, partitioned coloration and bleaching can be implemented, and an administration position can be accurately located.

Abstract: The present disclosure relates to processes for preparing 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one.

Abstract: Provided are a series of 5,6-dihydrothieno[3,4-h]quinazoline compounds as represented by formula (P) and pharmaceutically acceptable salts thereof, and the use of the compounds or pharmaceutically acceptable salts thereof in the preparation of solid tumor drugs, such as solid tumor drugs associated with selective PLK1 inhibitors.

Abstract: Disclosed are a class of compounds represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a piperazine bridge-substituted heterocyclic pyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically disclosed is a compound represented by formula (III-1) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Abstract: Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

Abstract: Disclosed in the present invention are a series of coumarin compounds and the uses thereof, and particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: A crystal form of a pyrimidine heterocyclic compound and a preparation method therefor. Specifically disclosed are a preparation method for and application of a compound of formula (II) and the crystal form thereof.

Abstract: The present disclosure relates to processes for preparing 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one.

Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Abstract: Provided are a sulfur/phosphorus-containing aryl compound and an application thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.

Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to processes for preparing 64(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one.

Abstract: Provided are a series of 5,6-dihydrothieno[3,4-h]quinazoline compounds as represented by formula (P) and pharmaceutically acceptable salts thereof, and the use of the compounds or pharmaceutically acceptable salts thereof in the preparation of solid tumor drugs, such as solid tumor drugs associated with selective PLK1 inhibitors.

Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.